TELA Bio, Inc.
NASDAQ:TELAMedical - Devices
+$0.09 today
- Market cap
- $51.00M
- Beta
- 1.36
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.72
Volume 0.22M
Average 0.17M
TELA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
TELA Bio, Inc.NASDAQ: TELA
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures declines year over year
Q2 FY2026 capital expenditures of $59K (cash outflow) fell 48.2% year over year, behind the -9.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 50.4% from the prior quarter. Over 3 fiscal years it compounded at -37.9% a year.
Context
- Capital expenditures amounted to 0.6% of revenue in FY2025, down 0.9 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -48.2% toward the trailing-twelve-month pace of -9.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (448K) USD
- Year-over-year change
- +54.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (448K) | +54.7% |
| FY2024 | 2024-12-31 | (989K) | -61.9% |
| FY2023 | 2023-12-31 | (611K) | +67.4% |
| FY2022 | 2022-12-31 | (1.87M) | -198.6% |
| FY2021 | 2021-12-31 | (627K) | — |
Capital Expenditures vs competitors
How TELA compares with its peers on the latest reported figures
- TELA's LTM Jun 2026 capital expenditures of $480K is the 2nd largest of the 9 companies compared; the peer median is $5K.
- Its year-over-year change of -9.8% is the 3rd highest of 5, against a peer median of -20.5%.
- Capital expenditures amounts to 0.6% of revenue for TELA, versus a peer median of 0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MDAISpectral AI, Inc. | LTM Mar 2026 | $3.73M | — | — | 22.3% |
| LTM Jun 2026 | $480K | -9.8% | -37.9% | 0.6% | |
| LTM Mar 2026 | $192K | +284.0% | +7.2% | 0.9% | |
| LTM Mar 2026 | $148K | -8.1% | +1.2% | 0.5% | |
| LTM Mar 2026 | $47K | -32.9% | -44.4% | — | |
| LTM Mar 2026 | $10K | — | — | — | |
| LTM Mar 2026 | $3 | -400.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TELA) | $5K | -20.5% | +1.2% | 0.2% | |
Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.28M) | (44.3M) | (46.66M) | (37.84M) | (38.83M) |
| Depreciation & Amortization | 535K | 1.19M | 808K | 1.01M | 1.01M |
| Deferred Income Tax | 14K | 0 | 0 | (144K) | 230K |
| Stock-Based Compensation | 3.66M | 3.99M | 5.03M | 4.36M | 3.8M |
| Change in Working Capital | (3.47M) | (5.76M) | (1.67M) | (4.87M) | 1.5M |
| Accounts Receivables | (1.55M) | (2.42M) | (3.06M) | (762K) | (110K) |
| Inventory | (5.19M) | (6.07M) | (2.72M) | (2.97M) | (503K) |
| Accounts Payables | 1.6M | (884K) | 11K | 482K | 141K |
| Other Working Capital | 1.69M | 3.62M | 4.1M | (1.62M) | 1.97M |
| Other Non-Cash Items | 2.1M | 4.14M | 1.64M | (4.12M) | 4.08M |
| Operating Cash Flow | (30.43M) | (40.75M) | (40.86M) | (41.6M) | (28.22M) |
| Capital Expenditures | (627K) | (1.87M) | (611K) | (989K) | (448K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1.29M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (1M) | 12K | 5.44M | 0 |
| Investing Cash Flow | (627K) | (1.87M) | (599K) | 4.45M | 846K |
| Debt Repayment | 0 | 10M | 0 | 0 | 14.03M |
| Common Stock Issued | 585K | 34.4M | 46.34M | 42.92M | 11.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 105K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.55M) | (74K) | 138K | (205K) |
| Financing Cash Flow | 585K | 40.85M | 46.27M | 43.06M | 25.75M |
| Effect of Forex Changes | 11K | (144K) | 164K | 28K | (217K) |
| Net Change in Cash | (30.46M) | (1.91M) | 4.98M | 5.94M | (1.84M) |
| Free Cash Flow | (31.06M) | (42.62M) | (41.47M) | (42.58M) | (28.67M) |
TELA Bio, Inc.
NASDAQ:TELA
Intrinsic Alpha fair value
Locked
Current Price
$1.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.